AU2002344386B2 - S-omeprazole (esomeprazole) inclusion complex with cyclodextrins - Google Patents

S-omeprazole (esomeprazole) inclusion complex with cyclodextrins Download PDF

Info

Publication number
AU2002344386B2
AU2002344386B2 AU2002344386A AU2002344386A AU2002344386B2 AU 2002344386 B2 AU2002344386 B2 AU 2002344386B2 AU 2002344386 A AU2002344386 A AU 2002344386A AU 2002344386 A AU2002344386 A AU 2002344386A AU 2002344386 B2 AU2002344386 B2 AU 2002344386B2
Authority
AU
Australia
Prior art keywords
inclusion complex
omeprazole
cyclodextrin
complex
substantially pure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002344386A
Other languages
English (en)
Other versions
AU2002344386A1 (en
Inventor
Yusuf Khwaja Hamied
Dharmaraj Ramachandra Rao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cipla Ltd
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of AU2002344386A1 publication Critical patent/AU2002344386A1/en
Application granted granted Critical
Publication of AU2002344386B2 publication Critical patent/AU2002344386B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
AU2002344386A 2001-06-06 2002-06-06 S-omeprazole (esomeprazole) inclusion complex with cyclodextrins Ceased AU2002344386B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0113792.6 2001-06-06
GB0113792A GB2376231A (en) 2001-06-06 2001-06-06 Benzimidazole-cyclodextrin inclusion complex
PCT/GB2002/002542 WO2002098423A1 (en) 2001-06-06 2002-06-06 S-omeprazole (esomeprazole) inclusion complex with cyclodextrins

Publications (2)

Publication Number Publication Date
AU2002344386A1 AU2002344386A1 (en) 2003-05-08
AU2002344386B2 true AU2002344386B2 (en) 2006-11-30

Family

ID=9916040

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002344386A Ceased AU2002344386B2 (en) 2001-06-06 2002-06-06 S-omeprazole (esomeprazole) inclusion complex with cyclodextrins

Country Status (17)

Country Link
US (1) US20040147481A1 (enExample)
EP (1) EP1401442B1 (enExample)
JP (1) JP2004536810A (enExample)
AT (1) ATE282412T1 (enExample)
AU (1) AU2002344386B2 (enExample)
CA (1) CA2449769C (enExample)
DE (1) DE60201995T2 (enExample)
ES (1) ES2232780T3 (enExample)
GB (1) GB2376231A (enExample)
LT (1) LT5182B (enExample)
LV (1) LV13154B (enExample)
NZ (1) NZ529956A (enExample)
PL (1) PL366940A1 (enExample)
PT (1) PT1401442E (enExample)
RU (1) RU2313343C2 (enExample)
WO (1) WO2002098423A1 (enExample)
ZA (1) ZA200309841B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1707217A1 (en) 2004-12-17 2006-10-04 Wacker Chemie AG Process for preparing an alpha lipoic acid/cyclodextrin complex and product prepared
US20060229277A1 (en) * 2005-04-08 2006-10-12 Orbus Pharma, Inc. Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
SI1973896T1 (sl) * 2005-12-28 2009-08-31 Union Quimico Farma Postopek priprave (S) - enantiomere omeprazola
KR20070069567A (ko) * 2005-12-28 2007-07-03 에스케이케미칼주식회사 저장안정성이 우수한 ｓ-오메프라졸 함유 포접 복합체 및이의 제조방법
WO2009040825A1 (en) 2007-09-25 2009-04-02 Hetero Drugs Limited A process for preparation of enantiomerically pure esomeprazole
WO2010097583A1 (en) * 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
CN104277030B (zh) * 2013-07-03 2016-04-20 湖南理工学院 一种反应萃取分离泮托拉唑对映体的方法
CN103768028A (zh) * 2014-01-15 2014-05-07 山东新时代药业有限公司 一种注射用埃索美拉唑钠无菌冻干粉末及其制备工艺

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3427787A1 (de) * 1984-07-27 1986-01-30 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Wirkstoffkomplexe von 5-methoxy-2((4-methoxy-3,5-dimethyl-2-pyridyl) methylsulfinyl)-1h-benzimidazol mit cyclodextrinen, deren herstellung und arzneimittel
TW224049B (enExample) * 1991-12-31 1994-05-21 Sunkyong Ind Ltd
US5877192A (en) * 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
JPH0948730A (ja) * 1995-06-02 1997-02-18 Takeda Chem Ind Ltd 水溶性の改善されたベンズイミダゾール系抗潰瘍剤含有安定組成物
AU5780696A (en) * 1995-06-02 1996-12-18 Takeda Chemical Industries Ltd. Stabilized composition comprising an antiulcerative benzimid azole
SE510666C2 (sv) 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
JP4608031B2 (ja) * 1997-03-13 2011-01-05 ヘキサル アーゲー アミノ酸／シクロデキストリン混合物による酸感受性ベンズイミダゾール類の安定化
PT1018340E (pt) * 1999-01-06 2003-12-31 Tecnimede Sociedade Tecnico Medicinal Sa Complexos de inclusao de sais de aminoacidos de derivados do benzimidazol com ciclodextrinas, sua preparacao e formulacoes farmaceuticas que os contem
KR100712039B1 (ko) * 1999-08-26 2007-04-27 에이에이아이파머 인코포레이티드 알콕시로 치환된 벤즈이미다졸 화합물, 상기 화합물을포함하는 약학적 제제, 및 상기 화합물의 이용방법
US6262085B1 (en) * 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
SE9903831D0 (sv) * 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles

Also Published As

Publication number Publication date
EP1401442A1 (en) 2004-03-31
JP2004536810A (ja) 2004-12-09
RU2003137221A (ru) 2005-06-10
CA2449769C (en) 2010-12-14
RU2313343C2 (ru) 2007-12-27
DE60201995T2 (de) 2005-11-24
ES2232780T3 (es) 2005-06-01
HK1064602A1 (en) 2005-02-04
PL366940A1 (en) 2005-02-07
LT2003100A (en) 2004-09-27
ATE282412T1 (de) 2004-12-15
US20040147481A1 (en) 2004-07-29
ZA200309841B (en) 2005-03-14
LT5182B (lt) 2004-12-27
GB0113792D0 (en) 2001-07-25
PT1401442E (pt) 2005-02-28
GB2376231A (en) 2002-12-11
EP1401442B1 (en) 2004-11-17
CA2449769A1 (en) 2002-12-12
DE60201995D1 (de) 2004-12-23
WO2002098423A1 (en) 2002-12-12
LV13154B (en) 2004-07-20
NZ529956A (en) 2005-07-29

Similar Documents

Publication Publication Date Title
US6410569B1 (en) Salt form of pantoprazole
HUP0400781A2 (hu) Eljárás (R)- vagy (S)-lansoprazol kristályosítására, az előállított kristályok, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk
WO2001002389A1 (en) Crystals of benzimidazole compounds
DE69911159T2 (de) Cyclodextrin Einschlusskomplexe mit Aminosäuresalzen von Benzimidazolderivaten, deren Herstellung, sowie diese enthaltende pharmazeutische Zusammensetzungen
JPWO2006134877A1 (ja) 注射剤
AU2002344386B2 (en) S-omeprazole (esomeprazole) inclusion complex with cyclodextrins
PL199868B1 (pl) Trwały ciekły preparat inhibitora H⁺ , K⁺-ATPazy, sposób jego wytwarzania, zastosowanie glikolu polietylenowego i soli sodowej lub potasowej inhibitora H⁺ , K⁺-ATPazy oraz zastosowanie tego preparatu
AU2002344386A1 (en) S-omeprazole (esomeprazole) inclusion complex with cyclodextrins
KR20010089474A (ko) 개선된 화학적 제조 방법 및 제약 제형
JP3283252B2 (ja) ベンズイミダゾール化合物の結晶
DE602004011946T2 (de) Alkalisalze von protonenpumpen-hemmern
CH698658B1 (de) Orale pharmazeutische Formulierung mit schneller Freisetzung für Pyridylmethylsulfinyl-Benzimidazole.
HK1064602B (en) S-omeprazole (esomeprazole) inclusion complex with cyclodextrins
US20050171057A1 (en) Pantoprazole cyclodextrin inclusion complexes
US20090030044A1 (en) Crystal of Salt of Benzimidazole Compound
MXPA06012569A (es) Composicion farmaceutica estable que contiene derivados de bencimidazol, y metodo para fabricarla.
JP2001072675A (ja) ベンズイミダゾール化合物の結晶
DE10234617A1 (de) Neues Salz von (S)-Pantoprazol
CH697390B1 (de) Orale pharmazeutische Formulierung für Pyridylmethylsulfinyl-Benzimidazole und Verfahren zu ihrer Herstellung.
CH699254B1 (de) Orale pharmazeutische Formulierung für Pyridylmethylsulfinyl-Benzimidazole, enthaltend Aluminiumoxid, und Verfahren zu ihrer Herstellung.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired